Smith & Nephew plc SN.L
Composite 53/100; the shares have moved about 26% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 18/100 — a strong mark against it.
Valuation ranks 71/100 — a moderate point in its favour. Income ranks 70/100 — a moderate point in its favour. Quality ranks 59/100 — a slight point in its favour.
Momentum ranks 18/100 — a strong mark against it. Growth ranks 49/100 — a slight mark against it.
What the company does Smith & Nephew plc develops, manufactures, and markets medical devices and services across Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. Its portfolio includes knee and hip implants, trauma devices, arthroscopic technologies, and wound-care products used in minimally invasive procedures.
Key financials The company reports gross margins of 68.3%, operating margins of 14.0%, and net margins of 10.1%. ROE is 11.8%, ROA 5.3%, and ROCE 19.0%. Revenue grew 7.4% while EPS surged 70.4%, supported by strong cash generation (FCF yield 8.8%).
Stock health Sideravia scores the stock 65.2 overall, citing average quality but attractive valuation. Strength (70.9) and income (82.0) are positives, though momentum (41.3) lags. The Piotroski F-Score is 7/9 and Altman Z is 3.86, indicating moderate financial health.
Price vs fair value The stock trades at a **discount** of 8.60% to our fair-value estimate of 1318.94 and a **discount** of 11.90% to the 12-month target of 1359.00. - Forward P/E of 13.81 (vs trailing 22.19) suggests undemanding valuation (Valuation 66.3). - PEG of 0.23 and high FCF yield of 8.8% reinforce attractiveness. - Dividend yield of 3.3% with 52.7% payout supports income appeal (Income 82.0).
Looking forward Analysts (n=17) expect further multiple expansion as growth normalizes. Near-term momentum remains soft (RSI 66.60), but long-term fundamentals (margin stability, cash flow) support the valuation discount.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.